US-based Ainos, a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, has begun marketing the Ainos SARS-CoV-2 Antigen Rapid Self-Test under an Emergency Use Authorization (EUA) issued by the Taiwan Food and Drug Administration (TFDA)  to Taiwan Carbon Nano Technology Corporation (TCNT), the manufacturer and product co-developer of the test in conjunction with Ainos. Ainos is the exclusive master sales and marketing agent for the COVID-19 Antigen Self-Test Kit.

The Company has been marketing the Ainos COVID-19 Rapid Test Kit for use by healthcare professionals in Taiwan under an EUA issued by the TFDA to TCNT since June 2021.

Building on the diagnostics technology of its professional-use test kits, the Ainos COVID-19 Antigen Self-Test Kit is for at-home use and intended for the qualitative detection of SARS-CoV-2 virus from direct nasal swab specimens collected by individual users. The test is designed to detect whether SARS-CoV-2, including the Omicron variant, is present in a sample and deliver results in as little as 15 minutes.

Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, "The growth in COVID-19 cases from the Omicron variant has significantly increased demand for at-home testing in Taiwan. Making accurate and rapid diagnostic tools such as the Ainos COVID-19 Antigen Self-Test Kit available for use by both individuals and healthcare professionals is vital for the detection and control of COVID-19."